Monoclonal antibody therapy in breast cancer
A new trend has been taking place in the daily oncology practice in the past twenty years: we are progressively moving toward individualized and personalized treatments. The treatment of breast cancer is one of the best examples to underline the outstanding effectiveness of the individualized approach. The modern molecular pathology features are capable of predicting the biological behavior of the tumors which gives a new basis for our therapeutic choices, both for neoadjuvant and adjuvant settings, as well as for metastatic disease. In our paper we review the currently used monoclonal antibodies in the treatment of breast cancer and provide an overview of the new research and future directions in this field.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2013 |
|---|---|
| Erschienen: |
2013 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:57 |
|---|---|
| Enthalten in: |
Magyar onkologia - 57(2013), 3 vom: 10. Sept., Seite 157-65 |
| Sprache: |
Ungarisch |
|---|
| Weiterer Titel: |
Monoklonális antitest-terápia emlõrákban |
|---|
| Beteiligte Personen: |
Dank, Magdolna [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 10.01.2014 Date Revised 10.12.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
MagyOnkol.2013.57.3.157 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM231530706 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM231530706 | ||
| 003 | DE-627 | ||
| 005 | 20231224090941.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2013 xx |||||o 00| ||hun c | ||
| 024 | 7 | |a MagyOnkol.2013.57.3.157 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0771.xml |
| 035 | |a (DE-627)NLM231530706 | ||
| 035 | |a (NLM)24107821 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a hun | ||
| 100 | 1 | |a Dank, Magdolna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Monoclonal antibody therapy in breast cancer |
| 246 | 3 | 3 | |a Monoklonális antitest-terápia emlõrákban |
| 264 | 1 | |c 2013 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.01.2014 | ||
| 500 | |a Date Revised 10.12.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a A new trend has been taking place in the daily oncology practice in the past twenty years: we are progressively moving toward individualized and personalized treatments. The treatment of breast cancer is one of the best examples to underline the outstanding effectiveness of the individualized approach. The modern molecular pathology features are capable of predicting the biological behavior of the tumors which gives a new basis for our therapeutic choices, both for neoadjuvant and adjuvant settings, as well as for metastatic disease. In our paper we review the currently used monoclonal antibodies in the treatment of breast cancer and provide an overview of the new research and future directions in this field | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Angiogenesis Inhibitors |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Maytansine |2 NLM | |
| 650 | 7 | |a 14083FR882 |2 NLM | |
| 650 | 7 | |a Bevacizumab |2 NLM | |
| 650 | 7 | |a 2S9ZZM9Q9V |2 NLM | |
| 650 | 7 | |a Panitumumab |2 NLM | |
| 650 | 7 | |a 6A901E312A |2 NLM | |
| 650 | 7 | |a EGFR protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a ErbB Receptors |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Trastuzumab |2 NLM | |
| 650 | 7 | |a P188ANX8CK |2 NLM | |
| 650 | 7 | |a Cetuximab |2 NLM | |
| 650 | 7 | |a PQX0D8J21J |2 NLM | |
| 650 | 7 | |a Ado-Trastuzumab Emtansine |2 NLM | |
| 650 | 7 | |a SE2KH7T06F |2 NLM | |
| 700 | 1 | |a Tõkés, Tímea |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Magyar onkologia |d 1961 |g 57(2013), 3 vom: 10. Sept., Seite 157-65 |w (DE-627)NLM092654185 |x 2060-0399 |7 nnns |
| 773 | 1 | 8 | |g volume:57 |g year:2013 |g number:3 |g day:10 |g month:09 |g pages:157-65 |
| 856 | 4 | 0 | |u http://dx.doi.org/MagyOnkol.2013.57.3.157 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 57 |j 2013 |e 3 |b 10 |c 09 |h 157-65 | ||